Advanced in Liposarcoma

Dr. Mary F. Mulcahy

Hematology | Oncology
Northwestern Medical Group
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
33 Years of Experience
Advanced in Liposarcoma
Northwestern Medical Group
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mary Mulcahy is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Mulcahy has been practicing medicine for over 33 years and is rated as an Advanced provider by MediFind in the treatment of Liposarcoma. Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Neuroendocrine Tumor, Liver Embolization, and Pancreaticoduodenectomy.

Her clinical research consists of co-authoring 120 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Liposarcoma.

Graduate Institution
University Of California San Diego School Of Medicine, 1993.0
Residency
Boston University Medical Center
Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Board Certifications
American Board Of Internal Medicine - Medical Oncology (Certified)
Fellowships
McGaw Medical Center of Northwestern University
Hospital Affiliations
Northwestern Memorial Hospital
Northwestern Lake Forest Hospital
Northwestern Medicine Mchenry
Palos Community Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Nippon Life
  • INSURANCE PLAN
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

675 N St Clair St Ste 21-100, Galter Pavilion, Chicago, IL 60611
Call: 866-587-4322

Additional Areas of Focus

Dr. Mulcahy has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma
Anal Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Enrollment Status: Recruiting
Publish Date: November 05, 2025
Intervention Type: Drug, Biological
Study Drugs: Fluorouracil, Irinotecan, Irinotecan hydrochloride, Leucovorin, Leucovorin calcium, Paclitaxel, Ramucirumab
Study Phase: Phase 2
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: February 12, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Enrollment Status: Active_not_recruiting
Publish Date: December 22, 2025
Intervention Type: Procedure, Drug
Study Drugs: Lutetium Lu 177 Dotatate, Triapine
Study Phase: Phase 1
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Procedure, Drug
Study Drugs: Berzosertib, Irinotecan
Study Phase: Phase 2
A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer
A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2025
Intervention Type: Drug, Radiation
Study Drug: Adavosertib
Study Phase: Phase 1
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: Ladiratuzumab Vedotin
Study Phase: Phase 2
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
Enrollment Status: Terminated
Publish Date: May 20, 2024
Intervention Type: Drug, Other
Study Drug: Tenofovir Alafenamide
Study Phase: Phase 3
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
Enrollment Status: Terminated
Publish Date: April 12, 2022
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
Enrollment Status: Completed
Publish Date: March 29, 2022
Intervention Type: Device
Study Phase: Not Applicable
Phase I/Ib Study of Nivolumab in Combination With Therasphere (Yttrium-90) in Patients With Advanced Hepatocellular Carcinoma
Phase I/Ib Study of Nivolumab in Combination With Therasphere (Yttrium-90) in Patients With Advanced Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: January 25, 2022
Intervention Type: Radiation, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 1
View 9 Less Clinical Trials

122 Total Publications

Intergroup Randomized Phase III Study of Adjuvant FOLFIRI, FOLFOX, or 5-FU/Leucovorin for Stage II/III Rectal Cancer: ECOG-ACRIN E3201.
Intergroup Randomized Phase III Study of Adjuvant FOLFIRI, FOLFOX, or 5-FU/Leucovorin for Stage II/III Rectal Cancer: ECOG-ACRIN E3201.
Journal: The oncologist
Published: May 15, 2025
View All 122 Publications
Similar Doctors
Distinguished in Liposarcoma
Dr. Samir D. Undevia
Hematology | Oncology
Distinguished in Liposarcoma
Dr. Samir D. Undevia
Hematology | Oncology

Endeavor Health Medical Group

801 S Washington St, Fl 3, 
Naperville, IL 
 (29.4 miles away)
630-527-5359
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Samir Undevia is a Hematologist and an Oncologist in Naperville, Illinois. Dr. Undevia is rated as a Distinguished provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Myxoid Liposarcoma, and Epithelioid Sarcoma. Dr. Undevia is currently accepting new patients.

Pedro A. Hermida
Distinguished in Liposarcoma
Dr. Pedro A. Hermida
Hematology | Oncology
Distinguished in Liposarcoma
Dr. Pedro A. Hermida
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Experience:
7+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Pedro Hermida is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Hermida has been practicing medicine for over 7 years and is rated as a Distinguished provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Bone Tumor, Synovial Sarcoma, Rhabdoid Tumor, Rhabdoid Tumor Predisposition Syndrome, and Gamma Knife Radiosurgery.

Distinguished in Liposarcoma
Dr. Marta Batus
Oncology
Distinguished in Liposarcoma
Dr. Marta Batus
Oncology

Rush University Medical Group

1620 W Harrison St, 
Chicago, IL 
 (3.2 miles away)
Languages Spoken:
English, Polish, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Marta Batus is an Oncologist in Chicago, Illinois. Dr. Batus is rated as an Elite provider by MediFind in the treatment of Liposarcoma. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Adult Soft Tissue Sarcoma, and Small Cell Lung Cancer (SCLC). Dr. Batus is currently accepting new patients.

VIEW MORE LIPOSARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mulcahy's expertise for a condition
ConditionClose
  • Elite
  • Colorectal Cancer
    Dr. Mulcahy is
    Elite
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
  • Distinguished
  • Adult Soft Tissue Sarcoma
    Dr. Mulcahy is
    Distinguished
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Alveolar Soft Part Sarcoma
    Dr. Mulcahy is
    Distinguished
    . Learn about Alveolar Soft Part Sarcoma.
    See more Alveolar Soft Part Sarcoma experts
  • Anal Cancer
    Dr. Mulcahy is
    Distinguished
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Appendix Cancer
    Dr. Mulcahy is
    Distinguished
    . Learn about Appendix Cancer.
    See more Appendix Cancer experts
  • Bone Tumor
    Dr. Mulcahy is
    Distinguished
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Cholangiocarcinoma (Bile Duct Cancer)
    Dr. Mulcahy is
    Distinguished
    . Learn about Cholangiocarcinoma (Bile Duct Cancer).
    See more Cholangiocarcinoma (Bile Duct Cancer) experts
View All 22 Distinguished Conditions
  • Advanced
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Mulcahy is
    Advanced
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Mulcahy is
    Advanced
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Mulcahy is
    Advanced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Ampullary Cancer
    Dr. Mulcahy is
    Advanced
    . Learn about Ampullary Cancer.
    See more Ampullary Cancer experts
  • Angiosarcoma
    Dr. Mulcahy is
    Advanced
    . Learn about Angiosarcoma.
    See more Angiosarcoma experts
  • Breast Cancer
    Dr. Mulcahy is
    Advanced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
View All 49 Advanced Conditions
  • Experienced
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Mulcahy is
    Experienced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Mulcahy is
    Experienced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Adrenal Cancer
    Dr. Mulcahy is
    Experienced
    . Learn about Adrenal Cancer.
    See more Adrenal Cancer experts
  • Adrenocortical Carcinoma
    Dr. Mulcahy is
    Experienced
    . Learn about Adrenocortical Carcinoma.
    See more Adrenocortical Carcinoma experts
  • Agranulocytosis
    Dr. Mulcahy is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Anaplastic Thyroid Cancer
    Dr. Mulcahy is
    Experienced
    . Learn about Anaplastic Thyroid Cancer.
    See more Anaplastic Thyroid Cancer experts
View All 71 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.